Benson Rony, Giridhar Prashant, Venkatesulu Bhanu Prasad, Mallick Supriya, Raza Mohd Waseem, Rath Goura Kishor
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
J Egypt Natl Canc Inst. 2017 Mar;29(1):1-9. doi: 10.1016/j.jnci.2016.07.002. Epub 2016 Aug 29.
Local recurrences after curative treatment have a potential for cure with salvage surgery or with re-irradiation.
We reviewed the PubMed for articles published in English with key words squamous cell carcinoma, recurrent, re-irradiation, prognostic factors to find relevant articles describing prognostic factors, re-irradiation, and outcome for recurrent head and neck squamous cell carcinoma.
Various factors including age, performance status, time for recurrence, previous radiation dose volume and site of recurrence, previous use of chemotherapy are all prognostic factors in recurrent head and neck squamous cell carcinoma. Surgery is feasible in very select subgroup of patients and must be done when feasible. Re-irradiation with the aid of modern sophisticated technology is safe and confers durable and clinically meaningful survival benefit. Re-irradiation in head and neck recurrent squamous cell carcinoma may provide an expected median survival of 10-12months. Chemotherapy may be added along with radiation in the recurrent setting.
Treatment approaches may have to be personalized. Re surgery must be done in all patients in whom it is feasible. In patients in whom surgery is not feasible, re-irradiation must be evaluated as a therapeutic option especially in patients with limited volume recurrence.
根治性治疗后局部复发有可能通过挽救性手术或再次放疗治愈。
我们在PubMed上检索了以英文发表的文章,关键词为鳞状细胞癌、复发、再次放疗、预后因素,以查找描述复发性头颈部鳞状细胞癌的预后因素、再次放疗及结果的相关文章。
包括年龄、体能状态、复发时间、既往放疗剂量体积和复发部位、既往化疗使用情况等多种因素均为复发性头颈部鳞状细胞癌的预后因素。手术仅在极少数特定亚组患者中可行,可行时必须进行。借助现代先进技术进行再次放疗是安全的,可带来持久且具有临床意义的生存获益。头颈部复发性鳞状细胞癌再次放疗可使预期中位生存期达到10至12个月。在复发情况下可联合化疗与放疗。
治疗方法可能需个体化。可行时必须对所有患者进行再次手术。对于手术不可行的患者,尤其是复发范围有限的患者,必须评估再次放疗作为一种治疗选择。